Giant Biogene Holding Co., Ltd. (HKG:2367)

Giant Biogene Holding Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	4,853	6,306	4,030	2,504	1,331	7,103
Short-Term Investments	-	38.08	19.5	11.03	21.31	4.88
Trading Asset Securities	2,543	1,984	1,829	1,275	865.97	155.61
Cash & Short-Term Investments	7,396	8,329	5,878	3,790	2,218	7,263
Cash Growth	-16.54%	41.68%	55.11%	70.85%	-69.46%	270.86%
Accounts Receivable	388.54	201.87	141.28	102.03	69.42	65.64
Other Receivables	-	27.06	7.34	14.55	4.6	6.7
Receivables	388.54	228.92	148.62	116.57	74.02	72.34
Inventory	353.67	391.07	310.81	200.44	183.9	89.39
Other Current Assets	-	69.99	64.17	28.26	61.58	16.11
Total Current Assets	8,312	9,019	6,402	4,135	2,538	7,441
Property, Plant & Equipment	1,335	1,257	1,093	711.62	551.65	333.53
Long-Term Investments	227.36	420.53	451.84	-	-	-
Other Intangible Assets	4.93	4.98	5.82	7.36	6.75	7.6
Long-Term Deferred Tax Assets	1.41	0.52	0.91	1.11	1.19	1.35
Other Long-Term Assets	363.77	140.12	84.65	117.91	40.9	94.41
Total Assets	10,244	10,841	8,038	4,973	3,138	7,878

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	248.79	198.57	286.71	133.11	54.65	23.61
Accrued Expenses	-	73.36	61.36	40.72	28.5	28.93
Current Portion of Leases	8.44	6.43	4.7	1.56	0.88	-
Current Income Taxes Payable	102.84	70.35	117.02	116.72	75.02	71.36
Current Unearned Revenue	54.71	19.38	18.68	37.25	13.95	17.78
Other Current Liabilities	367.01	431.89	347.53	201.25	107.9	6,701
Total Current Liabilities	781.78	799.96	836	530.61	280.91	6,843
Long-Term Leases	3.82	3.26	2.01	1.17	1.71	-
Long-Term Unearned Revenue	15.63	16.32	18.93	19.58	18.18	17.58
Long-Term Deferred Tax Liabilities	71.33	97.09	61.2	50.68	0.4	0.77
Total Liabilities	872.56	916.64	918.14	602.03	301.19	6,861

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.07	0.07	0.07	0.06	0.06	0.06
Additional Paid-In Capital	-	5,146	2,736	1,695	1,597	7,160
Retained Earnings	-	4,864	4,229	2,619	1,167	164.8
Treasury Stock	-	-166.15	-0	-0	-0	-0
Comprehensive Income & Other	9,358	67.1	143.53	48.81	69.72	-6,308
Total Common Equity	9,358	9,911	7,108	4,362	2,833	1,017
Minority Interest	13.13	13.31	11.61	8.91	3.56	-
Shareholders' Equity	9,371	9,925	7,120	4,371	2,837	1,017
Total Liabilities & Equity	10,244	10,841	8,038	4,973	3,138	7,878

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	12.26	9.69	6.71	2.73	2.59	-
Net Cash (Debt)	7,384	8,319	5,872	3,787	2,216	7,263
Net Cash Growth	-16.61%	41.68%	55.04%	70.92%	-69.50%	270.86%
Net Cash Per Share	6.95	7.85	5.86	3.85	2.17	7.26
Filing Date Shares Outstanding	1,050	1,066	1,016	976	976	900
Total Common Shares Outstanding	1,050	1,066	1,016	976	976	900
Working Capital	7,530	8,219	5,566	3,604	2,257	598.28
Book Value Per Share	8.91	9.30	7.00	4.47	2.90	1.13
Tangible Book Value	9,353	9,906	7,102	4,355	2,827	1,009
Tangible Book Value Per Share	8.91	9.30	6.99	4.46	2.90	1.12
Buildings	-	590.42	580.02	285.49	225.79	184.61
Machinery	-	345.17	214.6	131.75	104.62	69.28
Construction In Progress	-	459.18	387.88	356.25	244.44	81.58
Leasehold Improvements	-	44.31	21.69	9.54	5.56	1.86

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Aug 23, 2026

Data Sources Report a data error